Newsroom
  • July 15 , 2020

    Immunotherapy with CAR T cells results in exceptional patient recovery

    In a clinical trial evaluating a novel immunotherapy option for cancer treatment, a child with rhabdomyosarcoma, a form of muscle cancer, that had spread to the bone marrow, showed no detectable cancer following treatment with chimeric antigen receptor (CAR) T cells that were engineered to target the HER2 protein on the surface of the cancer cells.
    Read more
  • July 15 , 2020

    Sylvester researchers identify protein target that might ease graft versus host disease

    In a new study published in Science Translational Medicine, Robert Levy, Ph.D., along with graduate student and first author Cameron Bader and colleagues, have shown that inhibiting the STING protein pathway could protect certain patients from graft versus host disease, the most serious complication from bone marrow (stem cell) transplants.
    Read more
  • July 15 , 2020

    Boosting immune memory could reduce cancer recurrence

    Blocking a newly identified "immune memory checkpoint" in immune cells could improve immunotherapy and help prevent cancers from recurring, according to new findings in mice and human samples by researchers at the UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine. The research was published this week in Nature Immunology.
    Read more
  • July 14 , 2020

    First Coronavirus Vaccine Tested in Humans Shows Early Promise

    An experimental coronavirus vaccine made by the biotech company Moderna provoked a promising immune response against the virus and appeared safe in the first 45 people who received it, researchers reported on Tuesday in The New England Journal of Medicine.
    Read more
  • July 13 , 2020

    Amgen Announces Additional Investment In BeiGene

    Amgen (NASDAQ:AMGN) today announced an additional investment of approximately $421 million in BeiGene's registered direct offering of ordinary shares
    Read more
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More
If you would like to get in touch with us, please click here. Contact us